皮肤性病诊疗学杂志2024，Vol.31Issue(11)：789-794,6.DOI:10.3969/j.issn.1674-8468.2024.11.011
磷酸二酯酶-4抑制剂治疗掌跖脓疱病的研究进展
Research progress on phosphodiesterase 4 inhibitors in the treatment of palmoplantar pustulosis
姚心怡 1高文丽 1李娟 1张峻岭2
作者信息
- 1. 天津中医药大学研究生院,天津 301617
- 2. 天津市中医药研究院附属医院,天津 300120
- 折叠
摘要
Abstract
Palmoplantar pustulosis(PPP)is a chronic recurrent inflammatory skin disease.Existing therapeutic methods cannot meet the demand by patients.Phosphodiesterase-4(PDE-4)is a key enzyme involved in the balance of immunocytes.It acts as a downstream mediator in the signaling pathways of a variety of cytokines which are associated with palmoplantar pustulosis and extensively regulate immune responses.Apremilast,as representative of the oral PDE-4 inhibitors,displays superior efficacy in clinical trials against palmoplantar pustulosis.Crisaborole has also been regulate to induce sustained improvement in skin lesions.This article reviews the research progress on PDE-4 inhibitors in treatment of palmoplantar pustulosis.关键词
掌跖脓疱病/磷酸二酯酶-4抑制剂/阿普米司特/克立硼罗Key words
palmoplantar pustulosis/PDE-4 inhibitor/Apremilast/Crisaborole引用本文复制引用
姚心怡,高文丽,李娟,张峻岭..磷酸二酯酶-4抑制剂治疗掌跖脓疱病的研究进展[J].皮肤性病诊疗学杂志,2024,31(11):789-794,6.
